Thermo Fisher Scientific Introduces Next-Generation Unmixing Beads to Enhance Accuracy & Performance in Spectral & Conventional Flow Cytometry

Thermo Fisher Scientific has introduced Invitrogen™ UltraComp eBeads™ Spectral Unmixing Beads to improve accuracy in spectral and conventional flow cytometry. These beads help researchers more accurately separate overlapping fluorescent signals, making it easier to distinguish many cell types quickly, track rare cells and achieve consistent performance across experiments.

Researchers who use flow cytometry as a tool for analyzing cellular phenotypes and functions require deeper insights into cells to better understand disease and discover targeted therapies. Spectral and high-parameter flow cytometry can provide a more comprehensive view of many cell types, but current solutions can lead to false positives and negatives, as well as background interference that limits analysis. UltraComp eBeads behave like real cells, reduce autofluorescence and enhance fluorochrome signal clarity, leading to more precise results.

This next-generation solution sets a new standard in compensation bead performance by offering support for the broadest variety of species on the market. UltraComp eBeads can bind with mouse, rat, hamster, rabbit or recombinant human antibodies.

“With this launch, scientists now have access to advanced compensation beads that perform like real cells and are compatible with the existing line of spectral and conventional flow cytometers in the market, including our recently introduced Attune™ Xenith™ flow cytometer,” said Trisha Dowling, Vice President/General Manager, Flow and Imaging Technologies. “With distinct separation of fluorochrome signals and fewer errors in flow cytometry data analysis, researchers will be able to confidently detect and quantify cell populations in their studies. We’re proud to support critical research that advances our understanding of some of the most pressing diseases.”

The product is designed for research use by immunologists and immuno-oncologists from academic institutions, pharmaceutical and biotechnology companies, and the flow cytometry core facilities that support them.

Features/Benefits

• Unmixing and compensation performance comparable to real cells

• Improved unmixing accuracy yielding more reliable results for cleaner signals

• Bright and consistent fluorophore signals and reduced fluorescence background noise

• Multispecies compatibility: binding with mouse, rat, hamster, rabbit, or recombinant human antibodies

• Supports all major laser lines: UV, violet, blue, green, yellow-green, red and IR

• Easy setup: Each drop contains both positive and negative populations, creating two distinct peaks that make it easier to prepare—even for high-parameter panels

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, visit www.thermofisher.com.